Literature DB >> 18347051

Yersinia pestis caf1 variants and the limits of plague vaccine protection.

Lauriane E Quenee1, Claire A Cornelius, Nancy A Ciletti, Derek Elli, Olaf Schneewind.   

Abstract

Yersinia pestis, the highly virulent agent of plague, is a biological weapon. Strategies that prevent plague have been sought for centuries, and immunization with live, attenuated (nonpigmented) strains or subunit vaccines with F1 (Caf1) antigen is considered effective. We show here that immunization with live, attenuated strains generates plague-protective immunity and humoral immune responses against F1 pilus antigen and LcrV. Y. pestis variants lacking caf1 (F1 pili) are not only fully virulent in animal models of bubonic and pneumonic plague but also break through immune responses generated with live, attenuated strains or F1 subunit vaccines. In contrast, immunization with purified LcrV, a protein at the tip of type III needles, generates protective immunity against the wild-type and the fully virulent caf1 mutant strain, in agreement with the notion that LcrV can elicit vaccine protection against both types of virulent plague strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347051      PMCID: PMC2346721          DOI: 10.1128/IAI.00105-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  58 in total

1.  Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.

Authors:  Kristin L DeBord; Deborah M Anderson; Melanie M Marketon; Katie A Overheim; R William DePaolo; Nancy A Ciletti; Bana Jabri; Olaf Schneewind
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

2.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

3.  The black death past and present. 2. Some historical problems.

Authors:  P Slack
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Jul-Aug       Impact factor: 2.184

Review 4.  Plague immunization. I. Past and present trends.

Authors:  K F Meyer; D C Cavanaugh; P J Bartelloni; J D Marshall
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

5.  Protection against Yersinia infection induced by non-virulence-plasmid-encoded antigens.

Authors:  M Simonet; P Berche; D Mazigh; M Veron
Journal:  J Med Microbiol       Date:  1985-10       Impact factor: 2.472

6.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).

Authors:  K J Davis; D L Fritz; M L Pitt; S L Welkos; P L Worsham; A M Friedlander
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

7.  Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis.

Authors:  C Heilmann; O Schweitzer; C Gerke; N Vanittanakom; D Mack; F Götz
Journal:  Mol Microbiol       Date:  1996-06       Impact factor: 3.501

Review 8.  Intraspecific diversity of Yersinia pestis.

Authors:  Andrey P Anisimov; Luther E Lindler; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

10.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  44 in total

1.  Oral administration of a recombinant attenuated Yersinia pseudotuberculosis strain elicits protective immunity against plague.

Authors:  Wei Sun; Shilpa Sanapala; Hannah Rahav; Roy Curtiss
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

2.  Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.

Authors:  Paul M Arnaboldi; Mariya Sambir; Christina D'Arco; Lauren A Peters; Jos F M L Seegers; Lloyd Mayer; Alison A McCormick; Raymond J Dattwyler
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

3.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Authors:  Lauriane E Quenee; Nancy A Ciletti; Derek Elli; Timothy M Hermanas; Olaf Schneewind
Journal:  Vaccine       Date:  2011-07-16       Impact factor: 3.641

4.  LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.

Authors:  Wei Sun; Shilpa Sanapala; Jeremy C Henderson; Shandiin Sam; Joseph Olinzock; M Stephen Trent; Roy Curtiss
Journal:  Infect Immun       Date:  2014-08-11       Impact factor: 3.441

5.  Immunogenicity and safety of subunit plague vaccine: A randomized phase 2a clinical trial.

Authors:  Kai Chu; Jialei Hu; Fanyue Meng; Jingxin Li; Li Luo; Jianjun Xu; Zhonghang Yuan; Zhiyong Li; Wangeng Chen; Lei Jiao; Yali Chang; Bingxiang Wang; Yuemei Hu
Journal:  Hum Vaccin Immunother       Date:  2016-05-09       Impact factor: 3.452

6.  Yersinia pestis IS1541 transposition provides for escape from plague immunity.

Authors:  Claire A Cornelius; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

7.  Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Authors:  Lauriane E Quenee; Bryan J Berube; Joshua Segal; Derek Elli; Nancy A Ciletti; Deborah Anderson; Olaf Schneewind
Journal:  Vaccine       Date:  2009-12-10       Impact factor: 3.641

8.  Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis.

Authors:  R William Depaolo; Fangming Tang; Inyoung Kim; Mei Han; Nadine Levin; Nancy Ciletti; Anning Lin; Debra Anderson; Olaf Schneewind; Bana Jabri
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

9.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

10.  Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Authors:  Shilpa Sanapala; Hannah Rahav; Hetal Patel; Wei Sun; Roy Curtiss
Journal:  Vaccine       Date:  2016-04-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.